



July 18, 2014

Company Name	3 - D Matrix , Ltd .
A d d r e s s	3-2-4, Kojimachi, Chiyoda, Tokyo
P r e s i d e n t	Kentaro Takamura
Code Number	7777
C o n t a c t	Director Tomoyuki Arai
T E L	+81 3 (3511)3440

**Absorbable Hemostat “TDM-621”**  
**Product Registration Application Submitted in Indonesia**

The 3-D Matrix group is working towards commercialization of absorbable hemostat “TDM-621” globally. The company hereby announces that PT. Teguhindo Lestaritama (head office located at Jl. H Miran No. 32, Jakarta, Indonesia), our consolidated subsidiary 3-D Matrix Asia Pte. Ltd.’s sales and marketing partner for Indonesian market, has submitted the application for medical device product registration in Indonesia on July 18, 2014. This marks the second product registration submission in South East Asia, after our submission in Singapore on June 3, 2014.

The group has obtained CE marking for the absorbable hemostat “TDM-621” on January 14, 2014. This CE marking can be leveraged by using it as a reference regulatory agency approval in various countries in Asia-Pacific and Latin America. The product can be commercially marketed once approval is obtained in each country.

As the CE marking approval was utilized for application submitted in Indonesia, clinical trials are not required. Hence, once the Indonesian regulatory body, Ministry of Health, approves the product registration, commercialization activities can start. The group targets to begin commercial sales in Indonesia within current fiscal year (end of April 2015).

The company is currently focused on product launch in Europe. In the meantime, 3-D Matrix Asia Pte. Ltd. plans to continue to do the same in other markets in Asia-Pacific region, leveraging on the CE marking.

This announcement does not influence the earning forecast of the company at this moment. However, the group will make necessary announcements when it is deemed that there will be influence on the earning forecast of the company.